多囊卵巢综合征:心血管疾病的「风险增强」因素
多囊卵巢综合征(PCOS)是育龄女性最常见的内分泌疾病,以高雄激素血症、稀发排卵和多囊卵巢形态为特征。高雄激素表型与肥胖、血脂异常、血压升高和糖尿病前期或2型糖尿病等心血管代谢异常相关。许多但并非所有研究提示PCOS与心血管疾病(CVD)风险增加相关,包括冠心病和卒中,且独立于体重指数和传统危险因素。观察性数据的解读受PCOS和CVD定义及确认方法差异的限制。近期孟德尔随机化研究对PCOS与冠心病和卒中的因果关系提出了挑战。未来采用明确PCOS标准和更新遗传学方法的纵向研究可能有助于确定关联和因果关系。尽管如此,CVD风险筛查在该人群中仍至关重要,因为通过生活方式管理和药物治疗相结合可改善代谢谱并降低CVD风险。对于动脉粥样硬化性CVD风险升高的PCOS女性,应实施他汀类药物治疗。若CVD风险不确定,测量亚临床动脉粥样硬化(颈动脉斑块或冠状动脉钙化)可能是指导他汀起始治疗共同决策的有用工具。其他药物如二甲双胍和胰高血糖素样肽-1受体激动剂在胰岛素抵抗人群中也可能有助于降低CVD风险。需要额外研究以确定减轻PCOS相关CVD风险的最佳路径。
要点
- PCOS尤其高雄激素表型与肥胖、血脂异常、血压升高和糖尿病前期或2型糖尿病等心血管代谢异常相关。
- 许多但并非所有研究提示PCOS与冠心病和卒中风险增加相关,独立于体重指数和传统危险因素。
- 动脉粥样硬化性CVD风险升高的PCOS女性应实施他汀类药物治疗。
核心结论
- PCOS是CVD的风险增强因素,CVD风险筛查在该人群中至关重要。
- 动脉粥样硬化性CVD风险升高的PCOS女性应实施他汀类药物治疗。
- 若CVD风险不确定,测量亚临床动脉粥样硬化(颈动脉斑块或冠状动脉钙化)可能有助于指导他汀起始治疗的共同决策。
- 需要额外研究以确定减轻PCOS相关CVD风险的最佳路径。
研究设计与样本
- 综述类文章,检索范围原文未报告。
主要发现
- 许多但并非所有研究提示PCOS与CVD风险增加相关,包括冠心病和卒中,独立于体重指数和传统危险因素。
- 观察性数据的解读受PCOS和CVD定义及确认方法差异的限制。
- 近期孟德尔随机化研究对PCOS与冠心病和卒中的因果关系提出了挑战。
关键数值与推荐
- 原文未报告具体数值标准。
临床怎么用
- 动脉粥样硬化性CVD风险升高的PCOS女性应实施他汀类药物治疗。
- 若CVD风险不确定,测量亚临床动脉粥样硬化(颈动脉斑块或冠状动脉钙化)可能有助于指导他汀起始治疗的共同决策。
- 其他药物如二甲双胍和胰高血糖素样肽-1受体激动剂在胰岛素抵抗人群中也可能有助于降低CVD风险。
局限性
- 观察性数据的解读受PCOS和CVD定义及确认方法差异的限制。
- 近期孟德尔随机化研究对PCOS与冠心病和卒中的因果关系提出了挑战。
- 需要额外研究以确定减轻PCOS相关CVD风险的最佳路径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age and is hallmarked by hyperandrogenism, oligo-ovulation, and polycystic ovarian morphology. Polycystic ovary syndrome, particularly the hyperandrogenism phenotype, is associated with several cardiometabolic abnormalities, including obesity, dyslipidemia, elevated blood pressure, and prediabetes or type 2 diabetes. Many, but not all, studies have suggested that PCOS is associated with increased risk of cardiovascular disease (CVD), including coronary heart disease and stroke, independent of body mass index and traditional risk factors. Interpretation of the data from these observational studies is limited by the varying definitions and ascertainment of PCOS and CVD across studies. Recent Mendelian randomization studies have challenged the causality of PCOS with coronary heart disease and stroke. Future longitudinal studies with clearly defined PCOS criteria and newer genetic methodologies may help to determine association and causality. Nevertheless, CVD risk screening remains critical in this patient population, as improvements in metabolic profile and reduction in CVD risk are achievable with a combination of lifestyle management and pharmacotherapy. Statin therapy should be implemented in women with PCOS who have elevated atherosclerotic CVD risk. If CVD risk is uncertain, measurement of subclinical atherosclerosis (carotid plaque or coronary artery calcium) may be a useful tool to guide shared decision-making about initiation of statin therapy. Other medications, such as metformin and glucagon-like peptide-1 receptor agonists, also may be useful in reducing CVD risk in insulin-resistant populations. Additional research is needed to determine the best pathways to mitigate PCOS-associated CVD risk.
引用
- Guan C, Zahid S, Minhas AS, et al. Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease. Fertil Steril. 2022. PMID: 35512976. doi:10.1016/j.fertnstert.2022.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。